Oxaliplatinum in combination with 5-FU/FA in first-line chemotherapy of metastatic colorectal cancer: a new era in therapeutic strategy

首页> 外文期刊>Tumori. >Oxaliplatinum in combination with 5-FU/FA in first-line chemotherapy of metastatic colorectal cancer: a new era in therapeutic strategy

【24h】

Oxaliplatinum in combination with 5-FU/FA in first-line chemotherapy of metastatic colorectal cancer: a new era in therapeutic strategy

机译：奥沙利铂联合5-FU / FA在转移性结直肠癌一线化疗中的治疗策略新时代

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Tumori.》 |2000年第2期|共5页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 ita
中图分类肿瘤学;
关键词
Adenocarcinoma; Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; 腺癌; 抗肿瘤药; 结肠直肠肿瘤; 氟尿嘧啶; 草酸盐类; 铂化合物;

机译：Adenocarcinoma;Antineoplastic Agents;Colorectal Neoplasms;Fluorouracil;腺癌;抗肿瘤药;结肠直肠肿瘤;氟尿嘧啶;草酸盐类;铂化合物;
入库时间 2022-08-18 19:45:09

相似文献

外文文献
中文文献
专利

1. Oxaliplatinum in combination with 5-FU/FA in first-line chemotherapy of metastatic colorectal cancer: a new era in therapeutic strategy [J] . Tumori. . 2000,第2期

机译：奥沙利铂联合5-FU / FA在转移性结直肠癌一线化疗中的治疗策略新时代
2. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No. 150 and part review of technology appraisal No. 118): a systematic review and economic model [J] . Health technology assessment: HTA . 2013,第14期

机译：一线化疗后西妥昔单抗（单药或联合化疗），贝伐单抗（与非奥沙利铂化疗联合）和帕尼单抗（单药）治疗转移性结直肠癌的临床疗效和成本效益（技术评估编号第150号技术评估和第118号技术评估的部分复审：系统复审和经济模型
3. 664 PUBLICATION Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC) [J] . European Journal of Cancer Supplements . 2005,第2期

机译：664出版物西妥昔单抗联合伊立替康/ 5-氟尿嘧啶（5-FU）/亚叶酸（FA）（FOLFIRI）用于转移性结直肠癌（mCRC）的一线治疗
4. Is High-Dose Chemotherapy Plus Stem-Cell Transplant the Standard Treatment for Patients Failing First-Line Chemotherapy for Metastatic Germ Cell Tumor? [C] . Christian Kollmannsberger, Lawrence Einhorn, Craig Nichols Genitourinary Cancers Symposium. . 2014

机译：高剂量化疗加干细胞移植对转移细胞肿瘤的一线化疗失败的患者的标准治疗吗？
5. Therapeutic Targeting of Chemotherapy-Resistant Colorectal Cancer Stem Cells with P73- and Trail-Based Small Molecules [D] . Prabhu, Varun Vijay. 2016

机译：基于P73和基于轨迹的小分子对化疗耐药的结直肠癌干细胞的治疗靶向
6. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy) bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. [O] . M Hoyle, L Crathorne, J Peters, -1

机译：一线化疗后西妥昔单抗（单药或联合化疗）贝伐单抗（与非奥沙利铂化疗联合）和帕尼单抗（单药）治疗转移性结直肠癌的临床疗效和成本效益（技术评估编号第150号技术评估书和第118号技术评估书的一部分复审：系统的复审和经济模型。
7. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model [O] . Hoyle, M, Crathorne, Louise, Peters, J, 2013

机译：一线化疗后西妥昔单抗（单药或联合化疗），贝伐单抗（与非奥沙利铂化疗联合）和帕尼单抗（单药）治疗转移性结直肠癌的临床疗效和成本效益（技术评估编号第150号技术评估和第118号技术评估的部分复审：系统复审和经济模型

Oxaliplatinum in combination with 5-FU/FA in first-line chemotherapy of metastatic colorectal cancer: a new era in therapeutic strategy

著录项

相似文献

相关主题

期刊订阅